The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World

Ravi Jhaveri

doi:10.1016/j.clinthera.2021.03.007

The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World

Ravi Jhaveri^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.

Original language	English (US)
Pages (from-to)	702-710
Number of pages	9
Journal	Clinical Therapeutics
Volume	43
Issue number	4
DOIs	https://doi.org/10.1016/j.clinthera.2021.03.007
State	Published - Apr 2021

Keywords

COVID
SARS-CoV-2
baculovirus
recombinant adenovirus
vaccines

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clinthera.2021.03.007

Cite this

@article{e137f3226d164fcfa5b793be0f52416e,

title = "The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World",

abstract = "The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.",

keywords = "COVID, SARS-CoV-2, baculovirus, recombinant adenovirus, vaccines",

author = "Ravi Jhaveri",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = apr,

doi = "10.1016/j.clinthera.2021.03.007",

language = "English (US)",

volume = "43",

pages = "702--710",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - The Next Set of COVID-19 Vaccines

T2 - Leveraging New Development Platforms to Increase Access for More People Around the World

AU - Jhaveri, Ravi

PY - 2021/4

Y1 - 2021/4

N2 - The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.

AB - The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther.

KW - COVID

KW - SARS-CoV-2

KW - baculovirus

KW - recombinant adenovirus

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85103731407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103731407&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2021.03.007

DO - 10.1016/j.clinthera.2021.03.007

M3 - Article

C2 - 33832783

AN - SCOPUS:85103731407

SN - 0149-2918

VL - 43

SP - 702

EP - 710

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 4

ER -

The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this